Skip to main content
Top
Published in: Clinical Rheumatology 2/2013

01-02-2013 | Original Article

What was your fracture risk evaluated by FRAX® the day before your osteoporotic fracture?

Authors: Bérengère Aubry-Rozier, Delphine Stoll, Marc-Antoine Krieg, Olivier Lamy, Didier Hans

Published in: Clinical Rheumatology | Issue 2/2013

Login to get access

Abstract

Osteoporotic fracture (OF) is one of the major causes of morbidity and mortality in industrialized countries. Switzerland is among the countries with the greatest risk. Our aim was (1) to calculate the FRAX® in a selected Swiss population the day before the occurrence of an OF and (2) to compare the results with the proposed Swiss FRAX® thresholds. The Swiss Association Against Osteoporosis proposed guidelines for the treatment of osteoporosis based on age-dependent thresholds. To identify a population at a very high risk of osteoporotic fracture, we included all consecutive patients in the active OF pathway cohort from the Lausanne University Hospital, Switzerland. FRAX® was calculated with the available data the day before the actual OF. People with a FRAX® body mass index (BMI) or a FRAX® (bone mineral density) BMD lower than the Swiss thresholds were not considered at high risk. Two-hundred thirty-seven patients were included with a mean age of 77.2 years, and 80 % were female. Major types of fracture included hip (58 %) and proximal humerus (25 %) fractures. Mean FRAX® BMI values were 28.0, 10.0, 13.0, 26.0, and 37.0 % for age groups 50–59, 60–69, 70–79, and 80–89 years old, respectively. Fifty percent of the population was not considered at high risk by the FRAX® BMI. FRAX® BMD was available for 95 patients, and 45 % had a T score < −2.5 standard deviation. Only 30 % of patients with a normal or osteopenic BMD were classified at high risk by FRAX® BMD. The current proposed Swiss thresholds were not able to classify at high risk in 50 to 70 % of the studied population the day before a major OF.
Literature
1.
go back to reference Lippuner K, Golder M, Greiner R (2005) Epidemiology and direct medical costs of osteoporotic fractures in men and women in Switzerland. Osteoporos Int 16:S8–S17PubMedCrossRef Lippuner K, Golder M, Greiner R (2005) Epidemiology and direct medical costs of osteoporotic fractures in men and women in Switzerland. Osteoporos Int 16:S8–S17PubMedCrossRef
2.
go back to reference Suhm N, Lamy O, Lippuner K (1999) Management of fragility fractures in Switzerland: results of a nationwide survey. Swiss Med Wkly 138:674–683 Suhm N, Lamy O, Lippuner K (1999) Management of fragility fractures in Switzerland: results of a nationwide survey. Swiss Med Wkly 138:674–683
3.
go back to reference Lippuner K, Johansson H, Kanis JA, Rizzoli R (2010) FRAX assessment of osteoporotic fracture probability in Switzerland. Osteoporos Int 21:381–389PubMedCrossRef Lippuner K, Johansson H, Kanis JA, Rizzoli R (2010) FRAX assessment of osteoporotic fracture probability in Switzerland. Osteoporos Int 21:381–389PubMedCrossRef
4.
go back to reference Krieg MA, Cornuz J, Ruffieux C et al (2006) Prediction of hip fracture risk by quantitative ultrasound in more than 7,000 Swiss women > or = 70 years of age: comparison of three technologically different bone ultrasound devices in the SEMOF study. J Bone Miner Res 21:1457–1463PubMedCrossRef Krieg MA, Cornuz J, Ruffieux C et al (2006) Prediction of hip fracture risk by quantitative ultrasound in more than 7,000 Swiss women > or = 70 years of age: comparison of three technologically different bone ultrasound devices in the SEMOF study. J Bone Miner Res 21:1457–1463PubMedCrossRef
5.
go back to reference Kanis JA, Borgstrom F, De Laet C et al (2005) Assessment of fracture risk. Osteoporos Int 16:581–589PubMedCrossRef Kanis JA, Borgstrom F, De Laet C et al (2005) Assessment of fracture risk. Osteoporos Int 16:581–589PubMedCrossRef
6.
go back to reference Lippuner K, Johansson H, Kanis JA, Rizzoli R (2009) Remaining lifetime and absolute 10-year probabilities of osteoporotic fracture in Swiss men and women. Osteoporos Int 20:1131–1140PubMedCrossRef Lippuner K, Johansson H, Kanis JA, Rizzoli R (2009) Remaining lifetime and absolute 10-year probabilities of osteoporotic fracture in Swiss men and women. Osteoporos Int 20:1131–1140PubMedCrossRef
7.
go back to reference Aubry-Rozier B, Stoll D, Hans D, So A, Krieg MA, Lamy O (2010) Increasing treatment from 19 to 67 % 1 year after an osteoporotic fracture with an active pathway. Proc Meeting of the Swiss Society of Rheumatology, Fribourg, Switzerland, 2010, Swiss medical weekly p 23 Aubry-Rozier B, Stoll D, Hans D, So A, Krieg MA, Lamy O (2010) Increasing treatment from 19 to 67 % 1 year after an osteoporotic fracture with an active pathway. Proc Meeting of the Swiss Society of Rheumatology, Fribourg, Switzerland, 2010, Swiss medical weekly p 23
8.
go back to reference Aubry-Rozier B, Stoll D, Hans D, Lamy O, Krieg MA (2010) What was your FRAX the day before your hip fracture? Proc Meeting of ECCEO, Firenze, Italia, 2010, Osteoporos Int S72 Aubry-Rozier B, Stoll D, Hans D, Lamy O, Krieg MA (2010) What was your FRAX the day before your hip fracture? Proc Meeting of ECCEO, Firenze, Italia, 2010, Osteoporos Int S72
9.
go back to reference Kanis J, McCloskey EV, Johansson H, Oden A, Ström O, Borgström F (2010) Development and use of FRAX in osteoporosis. Osteoporos Int 21:S407–S413PubMedCrossRef Kanis J, McCloskey EV, Johansson H, Oden A, Ström O, Borgström F (2010) Development and use of FRAX in osteoporosis. Osteoporos Int 21:S407–S413PubMedCrossRef
10.
go back to reference Kanis JA, McCloskey EV, Johansson H, Strom O, Borgstrom F, Oden A (2009) How to decide who to treat. Best Pract Res Clin Rheumatol 23:711–726PubMedCrossRef Kanis JA, McCloskey EV, Johansson H, Strom O, Borgstrom F, Oden A (2009) How to decide who to treat. Best Pract Res Clin Rheumatol 23:711–726PubMedCrossRef
11.
go back to reference Johansson H, Kanis JA, McCloskey EV et al (2011) A FRAX(R) model for the assessment of fracture probability in Belgium. Osteoporos Int 22:453–461PubMedCrossRef Johansson H, Kanis JA, McCloskey EV et al (2011) A FRAX(R) model for the assessment of fracture probability in Belgium. Osteoporos Int 22:453–461PubMedCrossRef
12.
go back to reference Borgstrom F, Ström O, Coelho J, Johansson H, Oden A, McCloskey E, Kanis JA (2010) The cost-effectiveness of strontium ranelate in the UK for the management of osteoporosis. Osteoporos Int 21:339–349PubMedCrossRef Borgstrom F, Ström O, Coelho J, Johansson H, Oden A, McCloskey E, Kanis JA (2010) The cost-effectiveness of strontium ranelate in the UK for the management of osteoporosis. Osteoporos Int 21:339–349PubMedCrossRef
13.
go back to reference Borgstrom F, Ström O, Coelho J, Johansson H, Oden A, McCloskey EV, Kanis JA (2010) The cost-effectiveness of risedronate in the UK for the management of osteoporosis using the FRAX. Osteoporos Int 21:495–505PubMedCrossRef Borgstrom F, Ström O, Coelho J, Johansson H, Oden A, McCloskey EV, Kanis JA (2010) The cost-effectiveness of risedronate in the UK for the management of osteoporosis using the FRAX. Osteoporos Int 21:495–505PubMedCrossRef
14.
go back to reference Fraser LA, Langsetmo L, Berger C et al (2011) Fracture prediction and calibration of a Canadian FRAX(R) tool: a population-based report from CaMos. Osteoporos Int 22:829–837PubMedCrossRef Fraser LA, Langsetmo L, Berger C et al (2011) Fracture prediction and calibration of a Canadian FRAX(R) tool: a population-based report from CaMos. Osteoporos Int 22:829–837PubMedCrossRef
15.
go back to reference Sornay-Rendu E, Munoz F, Delmas PD, Chapurlat RD (2010) The FRAX tool in French women: how well does it describe the real incidence of fracture in the OFELY cohort? J Bone Miner Res 25:2101–2107PubMedCrossRef Sornay-Rendu E, Munoz F, Delmas PD, Chapurlat RD (2010) The FRAX tool in French women: how well does it describe the real incidence of fracture in the OFELY cohort? J Bone Miner Res 25:2101–2107PubMedCrossRef
16.
go back to reference Briot K et al (2010) Validity of FRAX to predict major osteoporotic fracture : data of the OPUS cohort. Proc Meeting of the French Society of Rheumatology, Paris, France, 2010, Joint bone spine p A43 Briot K et al (2010) Validity of FRAX to predict major osteoporotic fracture : data of the OPUS cohort. Proc Meeting of the French Society of Rheumatology, Paris, France, 2010, Joint bone spine p A43
17.
go back to reference Kanis JA, Oden A, Johansson H, McCloskey E (2012) Pitfalls in the external validation of FRAX. Osteoporos Int 23:423–431PubMedCrossRef Kanis JA, Oden A, Johansson H, McCloskey E (2012) Pitfalls in the external validation of FRAX. Osteoporos Int 23:423–431PubMedCrossRef
19.
go back to reference Leslie WD, Lix LM, Johansson H, Oden A, McCloskey E, Kanis JA (2011) Spine-hip discordance and fracture risk assessment: a physician-friendly FRAX enhancement. Osteoporos Int 22:839–847PubMedCrossRef Leslie WD, Lix LM, Johansson H, Oden A, McCloskey E, Kanis JA (2011) Spine-hip discordance and fracture risk assessment: a physician-friendly FRAX enhancement. Osteoporos Int 22:839–847PubMedCrossRef
Metadata
Title
What was your fracture risk evaluated by FRAX® the day before your osteoporotic fracture?
Authors
Bérengère Aubry-Rozier
Delphine Stoll
Marc-Antoine Krieg
Olivier Lamy
Didier Hans
Publication date
01-02-2013
Publisher
Springer-Verlag
Published in
Clinical Rheumatology / Issue 2/2013
Print ISSN: 0770-3198
Electronic ISSN: 1434-9949
DOI
https://doi.org/10.1007/s10067-012-2106-1

Other articles of this Issue 2/2013

Clinical Rheumatology 2/2013 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.